Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.87 USD
-1.00 (-3.46%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $27.88 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Immunovant, Inc. (IMVT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.93 | $57.00 | $46.00 | 76.41% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Immunovant, Inc. comes to $50.93. The forecasts range from a low of $46.00 to a high of $57.00. The average price target represents an increase of 76.41% from the last closing price of $28.87.
Analyst Price Targets (14)
Broker Rating
Immunovant, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, 15 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 15 | 15 |
Buy | 0 | 0 | 0 | 0 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.06 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/30/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
5/30/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
5/30/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
5/30/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
5/30/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
5/29/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
5/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/25/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
3/13/2024 | Goldman Sachs | Christopher Johnson | Not Available | Strong Buy |
2/15/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/13/2023 | UBS | Colin N Bristow | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 15 |
Average Target Price | $50.93 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | -0.52 |